Neth Heart J (2017) 25:335–342 DOI 10.1007/s12471-017-0965-4
ORIGINAL ARTICLE
Impact of airflow limitation in chronic heart failure S. Bektas1 · F. M. E. Franssen2,3 · V. van Empel1 · N. Uszko-Lencer1,3 · J. Boyne1 · C. Knackstedt1 · H. P. Brunner-La Rocca1
Published online: 27 February 2017 © The Author(s) 2017. This article is available at SpringerLink with Open Access.
Abstract Background Comorbidities are common in chronic heart failure (HF) patients, but diagnoses are often not based on objective testing. Chronic obstructive pulmonary disease (COPD) is an important comorbidity and often neglected because of shared symptoms and risk factors. Precise prevalence and consequences are not well known. Therefore, we investigated prevalence, pulmonary treatment, symptoms and quality of life (QOL) of COPD in patients with chronic HF. Methods 205 patients with stable HF for at least 1 month, aged above 50 years, were included from our outpatient cardiology clinic, irrespective of left ventricular ejection fraction. Patients performed post-bronchodilator spirometry, a six-minute walk test (6-MWT) and completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). COPD was diagnosed according to GOLD criteria. Restrictive lung function was defined as FEV1/FVC ≥0.70 and FVC 120/min) were excluded. Other exclusion criteria were recent surgery, recent myocardial infarction (80%, 50–80%, 30–50%, or
ORIGINAL ARTICLE
Impact of airflow limitation in chronic heart failure S. Bektas1 · F. M. E. Franssen2,3 · V. van Empel1 · N. Uszko-Lencer1,3 · J. Boyne1 · C. Knackstedt1 · H. P. Brunner-La Rocca1
Published online: 27 February 2017 © The Author(s) 2017. This article is available at SpringerLink with Open Access.
Abstract Background Comorbidities are common in chronic heart failure (HF) patients, but diagnoses are often not based on objective testing. Chronic obstructive pulmonary disease (COPD) is an important comorbidity and often neglected because of shared symptoms and risk factors. Precise prevalence and consequences are not well known. Therefore, we investigated prevalence, pulmonary treatment, symptoms and quality of life (QOL) of COPD in patients with chronic HF. Methods 205 patients with stable HF for at least 1 month, aged above 50 years, were included from our outpatient cardiology clinic, irrespective of left ventricular ejection fraction. Patients performed post-bronchodilator spirometry, a six-minute walk test (6-MWT) and completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). COPD was diagnosed according to GOLD criteria. Restrictive lung function was defined as FEV1/FVC ≥0.70 and FVC 120/min) were excluded. Other exclusion criteria were recent surgery, recent myocardial infarction (80%, 50–80%, 30–50%, or
